In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dendreon follow-on nets $197.4mm

Executive Summary

Oncology therapeutics company Dendreon closed the second largest follow-on public offering so far this year, netting $197.4mm through the sale of 10.7mm common shares at $19.20 apiece. The company will put some of the proceeds towards continued development and eventual launch of its lead candidate Provenge, which just proved a prolonged survival rate in Phase III clinical trials of men with advanced prostate cancer.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies